Evidence map›Paper›PMID 32052260›Full record

ArticleDocumenta ophthalmologica. Advances in ophthalmology2020

XEN Gel Stent in the management of primary open-angle glaucoma.

Michał Post, Wojciech Lubiński, Dominik Śliwiak, Karolina Podborączyńska-Jodko, Maciej Mularczyk

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Documenta ophthalmologica. Advances in ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 5 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 5 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. XEN Gel Stent Failure Due to Luminal Obstruction.Journal of ophthalmic & vision research
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Michał Post2nd Chair and Department of Ophthalmology, Pomeranian Medical University in Szczecin, Al. Powstańców Wlkp. 72, 70-111, Szczecin, Poland. info@okulistapost.pl.ORCID 0000-0002-0166-3696
Wojciech Lubiński2nd Chair and Department of Ophthalmology, Pomeranian Medical University in Szczecin, Al. Powstańców Wlkp. 72, 70-111, Szczecin, Poland.
Dominik Śliwiak2nd Chair and Department of Ophthalmology, Pomeranian Medical University in Szczecin, Al. Powstańców Wlkp. 72, 70-111, Szczecin, Poland.
Karolina Podborączyńska-Jodko2nd Chair and Department of Ophthalmology, Pomeranian Medical University in Szczecin, Al. Powstańców Wlkp. 72, 70-111, Szczecin, Poland.
Maciej MularczykChair and Department of Human and Clinical Anatomy, Pomeranian Medical University in Szczecin, Al. Powstańców Wlkp. 72, Szczecin, 70-111, Poland.
Pomeranian Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the efficacy and safety of the XEN Gel Stent in patients with primary open-angle glaucoma. MATERIALS AND

methodsTwenty eyes of 17 patients (6 males, 11 females) with primary open-angle glaucoma were implanted with XEN Gel Stent. The following data were ascertained in each participant at baseline and at 1, 3, 6, 9 and 12 months following implanting procedure: intraocular pressure, number of anti-glaucoma medications, retinal sensitivity (PS 24/2 w/w), pattern electroretinogram (ISCEV standard), as well as the number of complications.

resultsThe mean intraocular pressure reduction in a 1-year follow-up was 18% (21.56 vs. 17.69 mmHg, p < 0.001). The mean number of anti-glaucoma medications was reduced from 3.2 to 1.6 (p = 0.001). The PERG parameters at baseline and at 12 months postoperatively included a stable amplitude of P50 (2.55 µV vs. 2.65 µV, p = 0.024) and N95 (3.45 µV vs. 3.38 µV, p = ns) waves. The delta N95 and delta P50 amplitudes remained stable over the follow-up period (p = ns). The mean deviation (MD) of PS 24/2 was - 6.54 dB vs. - 8.43 dB, p = ns, whereas the pattern standard deviation (PSD) was 6.18 dB vs. 6.91 dB, p = ns. Transient hypotony within the first postoperative week occurred in 18 eyes (90%), whereas hyphema occurred in two eyes (10%). Needle revision of a filtration bleb was performed in five eyes (25%).

conclusionsThe XEN Gel Stent enables significant reduction in intraocular pressure with very low complication rates. It ensures a stabilization of the retinal function as established with the PERG.

Indexed as

Glaucoma Drainage ImplantsStentsAgedAntihypertensive AgentsElectroretinographyFemaleGlaucoma, Open-AngleHumansIntraocular PressureMaleMiddle AgedProsthesis ImplantationRetinaTonometry, OcularTreatment OutcomeAntihypertensive AgentsGlaucomaMIGSMinimally invasive glaucoma surgeryPattern electroretinogramPERGXEN

Identifiers

PMID32052260
PMCPMC7347710
OpenAlexW3006114451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.